Immutep Ltd
IMMP1.610USD
-0.080-4.73%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
2.35BMarktkapitalisierung
--KGV TTM
mehr Informationen über Immutep Ltd Unternehmen
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Unternehmensinformationen
BörsenkürzelIMMP
Name des UnternehmensImmutep Ltd
IPO-datumJun 23, 1988
CEOMr. Marc Voigt
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJun 23
AddresseLevel 32, Suite 32.07 Australia Square
StadtSYDNEY
BörseNASDAQ Global Market Consolidated
LandAustralia
Postleitzahl2000
Telefon61283157003
Websitehttps://www.immutep.com/
BörsenkürzelIMMP
IPO-datumJun 23, 1988
CEOMr. Marc Voigt
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Christian Mueller
Mr. Christian Mueller
Chief Development Officer
Chief Development Officer
--
--
Dr. Stephan Winckels
Dr. Stephan Winckels
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Eleanor Pearson
Ms. Eleanor Pearson
Investors Relation
Investors Relation
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 23
Aktualisiert: Sat, Aug 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.41%
Meridian Wealth Management, LLC
0.25%
AllianceBernstein L.P.
0.10%
Sender Company & Partners, Inc
0.08%
Andere
98.50%
Aktionäre
Aktionäre
Anteil
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.41%
Meridian Wealth Management, LLC
0.25%
AllianceBernstein L.P.
0.10%
Sender Company & Partners, Inc
0.08%
Andere
98.50%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
0.90%
Investment Advisor
0.88%
Research Firm
0.08%
Hedge Fund
0.03%
Individual Investor
0.01%
Venture Capital
0.01%
Andere
98.08%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
57
2.80M
1.91%
-1.07M
2025Q1
57
2.80M
1.92%
-1.15M
2024Q4
60
6.95M
4.78%
-4.23M
2024Q3
60
9.14M
6.30%
-2.51M
2024Q2
63
9.65M
6.65%
+2.67M
2024Q1
67
3.50M
2.94%
-1.44M
2023Q4
66
3.16M
2.65%
-1.77M
2023Q3
71
3.00M
2.53%
-4.97M
2023Q2
73
3.42M
3.09%
-6.79M
2023Q1
63
4.23M
4.80%
-5.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Pengana Capital Group Limited
970.61K
0.66%
--
--
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
648.31K
0.44%
-92.10K
-12.44%
Mar 31, 2025
Meridian Wealth Management, LLC
386.65K
0.26%
-7.50K
-1.90%
Mar 31, 2025
AllianceBernstein L.P.
140.05K
0.1%
+61.92K
+79.25%
Jun 30, 2024
UBS Financial Services, Inc.
24.01K
0.02%
+989.00
+4.30%
Mar 31, 2025
Steward Partners Investment Advisory, LLC
61.00K
0.04%
+61.00K
--
Mar 31, 2025
Susquehanna International Group, LLP
47.46K
0.03%
-68.66K
-59.13%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
45.49K
0.03%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
